NYSEAMERICAN:MTNB Matinas Biopharma (MTNB) Stock Price, News & Analysis $1.70 -0.01 (-0.55%) As of 10/23/2026 04:10 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsNews and TrendsOwnershipSEC Filings About Matinas Biopharma Stock (NYSEAMERICAN:MTNB) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Matinas Biopharma alerts:Sign Up Key Stats Today's Range$1.69▼$1.7850-Day Range$1.52▼$3.6252-Week Range$1.47▼$25.05Volume11,283 shsAverage Volume146,513 shsMarket Capitalization$1.67 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Matinas BioPharma, Inc. is a clinical-stage biotechnology company developing medicines based on its proprietary lipid nanocrystal (LNC) delivery technology. The platform is designed to improve the oral delivery of active pharmaceutical ingredients that may otherwise have limited absorption or require intravenous administration. The company’s lead program, MAT2203, is an oral formulation of amphotericin B, an antifungal medicine traditionally administered intravenously. Matinas has studied MAT2203 for serious systemic fungal infections, including cryptococcal meningitis, and has evaluated its potential to provide an orally administered alternative with fewer administration-related burdens. The company has also explored additional applications of its LNC platform for delivering other therapeutics, including anti-infective and nucleic acid-based medicines. Matinas BioPharma is headquartered in the United States and has focused its development activities on addressing significant unmet needs in infectious disease and drug delivery. Its programs remain subject to clinical development and regulatory review, and the company’s pipeline and priorities may change as research progresses.AI Generated. May Contain Errors. Read More Receive MTNB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Matinas Biopharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MTNB Stock News HeadlinesGH Power Signs Multi-Year Hydrogen Offtake Agreement with Change Energy for Hamilton Facility OutputSeptember 14, 2026 | globenewswire.comMatinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing StandardsSeptember 4, 2026 | globenewswire.comDo this before December or regret itPorter Stansberry believes President Trump will use the December G20 Summit in Miami to unveil a radical monetary reset tied to executive order 14241 - one he says could draw a sharp dividing line between prepared investors and those left behind. The last time America reset its money - under Nixon in the 1970s - it produced an average of 1,300 new millionaires per day for over 50 years. Stansberry's new documentary names a core group of assets he believes are positioned to surge as Trump's new dollar rolls out. Watch Porter Stansberry's full briefing and get his three steps to prepare before December.October 25 at 1:00 AM | Porter & Company (Ad)GH Power, Matinas BioPharma join forces to create NYSE-listed clean energy companyJuly 13, 2026 | msn.comMatinas BioPharma Announces Strategic Business Combination with GH Power to Create Publicly Traded, Advanced Clean Energy and Green Hydrogen Company; Signs Definitive Agreement ...July 13, 2026 | markets.businessinsider.comMatinas BioPharma Announces Strategic Business Combination with GH Power to Create Publicly Traded, Advanced Clean Energy and Green Hydrogen Company; Signs Definitive Agreement to Sell LNC Platform Technology and Lead Product Candidate MAT2203 to Azurity PharmaceuticalsJuly 13, 2026 | globenewswire.comMatinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards and Acceptance of Plan to Regain ComplianceJune 26, 2026 | globenewswire.comMatinas BioPharma Holdings, Inc.April 8, 2026 | edition.cnn.comSee More Headlines MTNB Stock Analysis - Frequently Asked Questions How have MTNB shares performed this year? Matinas Biopharma's stock was trading at $8.79 on January 1st, 2026. Since then, MTNB stock has decreased by 80.7% and is now trading at $1.7006. How were Matinas Biopharma's earnings last quarter? Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) released its earnings results on Thursday, August, 13th. The company reported ($3.15) EPS for the quarter. When did Matinas Biopharma's stock split? Matinas Biopharma's stock reverse split before market open on Monday, September 28th 2026.A 1-15 reverse split was announced. The number of shares owned by shareholders was adjusted after the market closes on Sunday, September 27th 2026. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. How do I buy shares of Matinas Biopharma? Shares of MTNB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Matinas Biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Matinas Biopharma investors own include SCYNEXIS (SCYX), Tesla (TSLA), Viking Therapeutics (VKTX), Kushco (KSHB), Oncobiologics (OTLK), NIO (NIO) and Bionano Genomics (BNGO). Company Calendar Last Earnings8/13/2026Today10/25/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (3m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 MTNB's financial health is in the Red zone, according to TradeSmith. MTNB has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNYSEAMERICAN:MTNB Previous SymbolNYSE:MTNB CIK1582554 Webmatinasbiopharma.com Phone(908) 484-8805FaxN/AEmployees2Year Founded2011Profitability EPS (Trailing Twelve Months)($3.89) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$10.35 million Net MarginsN/A Pretax MarginN/A Return on Equity-166.11% Return on Assets-102.20% Debt Debt-to-Equity RatioN/A Current Ratio0.85 Quick Ratio0.85 Sales & Book Value Annual Sales$1.10 million Price / Sales1.52 Cash FlowN/A Price / Cash FlowN/A Book Value$11.30 per share Price / Book0.15Miscellaneous Outstanding Shares980,000Free Float935,000Market Cap$1.67 million OptionableN/A Beta2.08 Social Links The 7 Best High-Yield Dividend Stocks for 2027Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.Get This Free Report This page (NYSEAMERICAN:MTNB) was last updated on 10/23/2026 by MarketBeat.com Staff. From Our PartnersWhy tech stocks are deadAI skeptics see dot-com era warning signs, and they have a point. But the real opportunity may not be in the b...Porter & Company | SponsoredEarth's biggest energy source: near Grand CanyonThe largest energy source on Earth contains 50,000 times every oil and gas reserve on the planet combined - an...Behind the Markets | SponsoredHow one gold strategy paid out 1127 dollars in a monthGold usually only pays off once its price climbs, and only after you sell. Tim Plaehn found a different route....Investors Alley | SponsoredElon Musk’s Hushed FCC Filing. Dec 8th.Elon Musk quietly filed a document with the federal government tied to artificial intelligence, one of the lar...Paradigm Press | SponsoredHe turned $12K into $1.65M without touching Apple or TeslaTim Sykes turned $12,415 in gift money into more than $1.65 million before graduating college, without trading...Tim Sykes | SponsoredWhy Gerardo Del Real says wait before buying uranium stocksGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | SponsoredMy next big call (under $1)17,556% on KDA. 3,900% on PRE. 2,650% on OCEAN. Every single one of these was recommended to our community bef...Crypto 101 Media | SponsoredStill haven't grabbed your midterm report?The Midterm Election Playbook normally sells for 29.97, but it is free today. With the midterms just weeks ...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Matinas Biopharma Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Matinas Biopharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
